Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
for Cervical Cancer
128 locations incl. Phoenix
Sponsor: Pfizer
Sex: Female·Age: 18+
Code: NCT06952660·Phase 4·Recruiting·Listed May 2025
Norton Cancer Institute, St. Matthews
Clinical research site in Louisville, Kentucky · Norton Cancer Institute - St. Matthews, 3991 Dutchmans Ln #405, Louisville, KY 40207 · (502) 899-3366 · Website
As of September 2026, 12 paid clinical trials are recruiting at Norton Cancer Institute, St. Matthews in Louisville, Kentucky. Active studies at this site cover conditions such as Cervical Cancer, Lymphoma, Large B-Cell, Diffuse and Epithelial Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
New trial at Norton Cancer Institute, St. Matthews? We'll email you when one opens.
Recruiting clinical trials at Norton Cancer Institute, St. Matthews (12)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
for Lymphoma, Large B-Cell, Diffuse
71 locations incl. Mobile
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
for Epithelial Ovarian Cancer
67 locations incl. Birmingham
Sponsor: AbbVie
Sex: Female·Age: 18+
Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
for Diffuse Large B-Cell Lymphoma
47 locations incl. Mobile
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06717347·Phase 3·Recruiting·Listed Dec 2024
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
for DLBCL
22 locations incl. Glendale
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT05139017·Phase 2, Phase 3·Recruiting·Listed Dec 2021
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
for Myelodysplastic Syndrome
41 locations incl. Duarte
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All·Age: 18+
Code: NCT04227847·Phase 1·Recruiting·Listed Jan 2020
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
for Acute Myeloid Leukemia
44 locations incl. Phoenix
Sponsor: Kura Oncology, Inc.
Sex: All·Age: 18+
Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
for Multiple Myeloma (MM)
20 locations incl. Gilbert
Sponsor: C4 Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT07280013·Phase 1·Recruiting·Listed Dec 2025
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
for Ovarian Cancer
21 locations incl. Birmingham
Sponsor: Regeneron Pharmaceuticals
Sex: Female·Age: 18+
Code: NCT06787612·Phase 2·Recruiting·Listed Jan 2025
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
for Systemic Lupus Erythematosus (With and Without Nephritis)
14 locations incl. Phoenix
Sponsor: Allogene Therapeutics
Sex: All·Age: 18 - 74
Code: NCT07085104·Phase 1·Recruiting·Listed Jul 2025
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
for CLL / SLL
5 locations incl. Louisville
Sponsor: Lomond Therapeutics Holdings, Inc.
Sex: All·Age: 18+
Code: NCT06708897·Phase 1·Recruiting·Listed Nov 2024
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
for Indolent B-Cell Non-Hodgkin Lymphoma
1 location in Louisville
Sponsor: BioInvent International AB
Sex: All·Age: 18+
Code: NCT03571568·Phase 1, Phase 2·Recruiting·Listed Jun 2018
Get new-trial alerts for Norton Cancer Institute, St. Matthews
We'll email you whenever a new clinical trial starts recruiting at this research site in Louisville, KY. Unsubscribe anytime.
More research sites in Louisville
- University of Louisville (62 trials)
- Norton Cancer Institute (36 trials)
- The James Graham Brown Cancer Center at University of Louisville (35 trials)
- UofL Health Medical Center Northeast (34 trials)
- Norton Children's Hospital (31 trials)
- Baptist Health Louisville (22 trials)
- University of Louisville Hospital (13 trials)
- Norton Healthcare (10 trials)
- Gastroenterology Health Partners (7 trials)
- Robley Rex VA Medical Center (6 trials)
Is this your research site?
This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.
Explore more
Paid clinical trials in Louisville, KY · Kentucky clinical trials